CLAIMS

1. An orally disintegrating pharmaceutical tablet comprising:
between 0.1 and 21 wt% of cariprazine or its pharmaceutically acceptable salts,
between 0.1 and 15 wt% of a disintegrant,
between 0.1 and 5 wt% of colloidal silicon dioxide,
between 0.1 and 10 wt% of a taste masking agent,
between 0.1 and 5 wt% of a lubricant, and
up to 100 wt% of a diluent,
the percentage being expressed with regard to the total weight of the pharmaceutical tablet.

2. The pharmaceutical tablet according to claim 1, wherein the pharmaceutically acceptable salt of cariprazine is the hydrochloride salt.

3. The pharmaceutical tablet according to claims 1 or 2, wherein the silicon dioxide is anhydrous colloidal silicon dioxide or hydrated colloidal silicon dioxide.

4. The pharmaceutical tablet according to claim 3, wherein the colloidal silicon dioxide is hydrated colloidal silicon dioxide.

5. The pharmaceutical tablet according to any one of claims 1 to 4, wherein the taste masking agent is an organic acid.

6. The pharmaceutical tablet according to claim 5, wherein the organic acid is selected from the group of oxalic acid, maleic acid, succinic acid, citric acid, tartaric acid, malic acid and combinations thereof.

7. The pharmaceutical tablet according to any one of claims 1 to 6, wherein the disintegrant is selected from the group of sodium starch glycolate, crospovidone, croscarmellose sodium and combinations thereof.

8. The pharmaceutical tablet according to any one of claims 1 to 7, wherein the diluent comprises mannitol, dextrates, isomalt, or sorbitol, or mixtures thereof with starch.

9. The pharmaceutical tablet according to claim 8, wherein the diluent is a mixture of 78.0 - 82.0 wt% D-mannitol and 15.0 - 19.0 wt% maize starch.

10. The pharmaceutical tablet according to any one of claims 1 to 9, wherein the lubricant is magnesium stearate or sodium stearyl fumarate.

11. The pharmaceutical tablet according to any one of claims 1 to 10, wherein the disintegrant is present in an amount between 0.1 wt% and 10 wt%.

12. The pharmaceutical tablet according to any one of claims 1 to 11, wherein the colloidal silicon dioxide is present in an amount between 0.1 wt% and 2 wt%.

13. The pharmaceutical tablet according to any one of claims 1 to 12, wherein the taste masking agent is present in an amount between 0.1 and 5 wt%.

14. The pharmaceutical tablet according to any one of claims 1 to 13, for use in the treatment and/or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

15. The pharmaceutical tablet for use according to claim 14, wherein the pathological condition is selected from the group of schizophrenia, bipolar disorder, and autism.

16. The use of the pharmaceutical tablet according to any one of claims 1 to 13 in the manufacture of a medicament for the treatment and/or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

17. The use according to claim 16, wherein the pathological condition is selected from the group of schizophrenia, bipolar disorder, and autism.